Targeted therapeutic drugs such as anaplastic lymphoma kinase (ALK) inhibitors (6) and epidermal growth factor receptor (EGFR) inhibitors (7) have showed a promising performance in clinical trials for treating lung cancer patients with ALK or EGFR mutations. The gene discussed is EGFR; the disease is lung cancer.